Galectin Therapeutics Inc. Stock Prediction
AI-powered sentiment analysis and prediction trends for GALT, updated each market day.
GALT AI Sentiment
AI sees no strong directional signal for Galectin Therapeutics Inc. stock over the next 10 market days.
Prediction date: June 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
Sector
Exchange
Market Cap
$278,574,678
Cap Tier
Employees
9
Headquarters
NORCROSS, GA
Listed Since
Sept. 4, 2002
GALT Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
GALT Volatility
Galectin Therapeutics Inc. has shown high price volatility over the last 5 trading days. High volatility means larger price swings — this can present both opportunity and risk for traders.
